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Background: Burkitt lymphoma(BL) is a high grade non-Hodgkin lymphoma, which may be 
underdiagnosed in South Africa, due to a high burden of infectious diseases such as HIV and 
TB which may present with similar clinical features.
Aim: To describe demographics and clinico-pathological characteristics of patients diagnosed 
with BL. 
Setting: Tygerberg Hospital (TBH), South Africa between 2007–2014.
Methods: We performed a retrospective descriptive and survival analysis of patients diagnosed 
with BL at TBH between 01 January 2007 and 31 December 2014 with at least 24-month follow-
up. Data was collected from the Tygerberg Lymphoma Study Group database and the South 
African Children Cancer Study Group Tumour Registry.
Results: There were 73 patients with BL, of whom 68 were admitted to TBH and whose data was 
further analysed. The majority of patients were adults (74%). There was a female predominance 
in adults and a male predominance in children ( p = 0.002). Various regimens were used in adults 
while a single treatment protocol was used in children. The proportion of patients with HIV and 
advanced BL was higher in adults than in children. The 2-year overall survival of the treatment 
group was 45%. The outcome of patients with BL in adults (34%) was poorer than that of children 
(69%) ( p = 0.022). HIV negative patients had a non-significant survival advantage (57%) over 
HIV positive patients with 41% 2-year overall survival ( p = 0.2876).
Conclusion: This study demonstrates a better cure rate in children treated for BL compared to 
adults, with HIV-infection being a risk factor for poor outcome.
Keywords: epidemiology; Burkitt lymphoma; human immunodeficiency virus; tuberculosis; 
children; adults; treatment; outcome; South Africa.
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Introduction
Burkitt’s lymphoma (BL) was first described in Eastern Africa, initially as sarcoma of the jaw, but 
later identified as a form of non-Hodgkin’s lymphoma.1 A diagnosis of BL is made if the bone 
marrow is involved.2 The disease becomes rapidly fatal if left untreated.3 With the development of 
intensive chemotherapy treatment protocols, the long-term survival has dramatically improved.4,5
Burkitt’s lymphoma accounts for more than 50% of all childhood cancers in endemic areas 
and for 40% – 50% of childhood non-Hodgkin’s lymphomas (NHLs) in non-endemic areas such 
as North America and Western Europe.6
Before the era of highly active anti-retroviral therapy (HAART), the incidence of BL was estimated 
to be 1000 times higher in human immunodeficiency virus (HIV)-positive patients than in the 
general population.7 More male patients are affected, with a male to female ratio ranging from 
2:1 to 3:1 reported amongst HIV-negative patients in American BL studies.8,9
The World Health Organization (WHO) Classification of Tumours of Haematopoietic and 
Lymphoid Tissues (revised 4th edition) divides BL into three clinical variants.10,11 The endemic 
variant is primarily found in African children aged 4–7 years and is twice more common in boys 
than in girls.12 The sporadic variant occurs worldwide. Immunodeficiency-associated BL can also 
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occur in patients with congenital or acquired 
immunodeficiency disorders or in organ transplant patients 
receiving immunosuppressive drugs.13
Burkitt’s lymphoma has three chromosomal translocations, 
namely t(8;14)(q24;q32) or its variants t(2;8) and t(8;22), 
involving myc oncogene at 8q24 with one of the 
immunoglobulin (Ig) loci partners such as IgHeavy at 
14q32 or IgKappa at 2p12 or IgLambda at 22q11.14
The WHO 2016 classification has added a new 
provisional entity designated ‘Burkitt-like lymphoma 
with 11q aberration’. This new entity has more complex 
karyotypes, lower levels of myc expression and a degree 
of morphological pleomorphism.15
The clinical symptoms depend on the clinical variant of BL.16 
The endemic variant usually involves the jaw or other facial 
bones,1 but can affect the gastrointestinal tract, ovaries, 
breasts and the central nervous system where it causes nerve 
damage resulting in weakness and paralysis.10,16 The sporadic 
and immunodeficiency-associated variants involve mainly 
the bowel, forming bulky abdominal tumour masses and 
massive hepatosplenomegaly. Bone marrow infiltration also 
occurs. Several staging systems are used, including the 
St. Jude/Murphy staging and Ann Arbor staging systems.
The introduction of intensive multi-agent chemotherapy 
resulted in improved outcomes in paediatric BL but 
also increased treatment toxicity in adults, especially the 
elderly.17 Surgical de-bulking is no longer recommended.18 
The standard treatment of BL is intensive multi-agent 
chemotherapy combined with good supportive care.19
Early intensive chemotherapy will usually cure BL in the 
majority of children, leading to long-term survival rates 
of up to 90%,20 depending on the treatment protocol and 
supportive care.21 The results are variable for adults.22,23,24,25 
Cure is also achieved in lower middle-income countries 
(LMICs) with modified treatment protocols.26
For Adults diagnosed with BL, the different protocols have 
been used based on risk stratification, namely LMB regimen 
(Course 1 COP: cyclophosphamide, vincristine, prednisone 
and intrathecal methotrexate; Course 2 COPAD 1: 
cyclophosphamide, vincristine, prednisone, doxorubicin 
and intrathecal methotrexate; Course 3 COPAD 2: 
cyclophosphamide, vincristine, prednisone, doxorubicin and 
intrathecal methotrexate; Course 4 CVM 1: cyclophosphamide, 
vincristine, methotrexate and intrathecal methotrexate; 
Course 5 CVM 1: cyclophosphamide, vincristine, 
methotrexate and intrathecal methotrexate); HyperCVAD 
regimen (Course A consists of cyclophosphamide, vincristine, 
doxorubicin [adriamycin], dexamethasone, cytarabine, 
mesna and methotrexate; Course B consists of methotrexate, 
leucovorin, sodium bicarbonate and cytarabine); CODOX-M 
with or without alternating IVAC regimen (CODOX-M 
regimen is as follows: cyclophosphamide, doxorubicin, 
vincristine, leucovorin rescue, intrathecal cytarabine and 
intrathecal methotrexate, while IVAC regimen is as follows: 
ifosfamide with mesna protection, etoposide, cytarabine and 
intrathecal methotrexate); CALGB (cancer and leukaemia 
group B) 9251 regimen (Course I consists of cyclophosphamide 
and prednisone; Courses II, IV, and VI comprise the following: 
ifosfamide, mesna, methotrexate, leucovorin, vincristine, 
cytarabine, etoposide and dexamethasone; Courses III, V, 
and VII comprise the following: cyclophosphamide, 
methotrexate, leucovorin, vincristine, adriamycin and 
dexamethasone; intrathecal chemotherapy consists of 
methotrexate plus cytarabine all administered on day 1 of 
each course [II-VII]); DA-EPOCH-R regimen (dose-adjusted 
etoposide, prednisolone, vincristine, cyclophosphamide, 
doxorubicin and rituximab); MACOP-B regimen 
(methotrexate, adriamycin, cyclophosphamide, vincristine, 
prednisone and bleomycin); CHOP regimen 
(cyclophosphamide, vincristine, doxorubicin and prednisone) 
and CHOEP regimen (cyclophosphamide, vincristine, 
doxorubicin, etoposide and prednisone). 6,10,16,17,25,26,27
For children, the French-American-British/LMB 1996 (FAB/
LMB-96) international study protocols currently achieve 90% 
cure for localised unresected disease. Even in high-risk BL, 
up to 90% cure rates have been reported.19,22
Multi-drug salvage regimens may be used in refractory 
disease28 and transplant options may be offered,27 but 
outcomes are variable and nowhere near as good as in the 
first-line response. Cyclophosphamide (CPM) is found to 
be an affordable chemotherapy for endemic BL in LMICs.26
Human immunodeficiency virus infection may mimic 
tuberculosis (TB) and/or BL. The socio-economic burden of 
multi-drug resistance TB (MDR-TB) on patients in LMICs is 
reported to be high.29 Therefore, undiagnosed BL or delayed 
diagnosis of BL in patients with HIV and/or acquired 
immunodeficiency syndrome (HIV and/or AIDS) and/or 
complicated TB may lead to depression, stigma, discrimination, 
psychological distress and financial hardship.30,31
South African HIV treatment roll-out started in 2004. Highly 
active anti-retroviral therapy was used from 2004 to 2012 and 
combined antiretroviral therapy (cART) was introduced in 
2013. This followed the National Guidelines for Management 
of HIV and was updated by the South African HIV Clinicians 
Society. This resulted in starting ART in all patients diagnosed 
with HIV infection regardless of the CD4 count or symptoms.32
South Africa has unique health and socio-economic 
challenges, similar to the rest of upper middle income 
countries (MIC) as defined by the World Bank’s analytical 
income classification 2014.
This study aims to document the number of patients with BL, 
to determine the treatment protocol used and patient 
outcomes and to compare patient outcomes between adults 
and children, as well as between HIV-infected and non-HIV-
infected patients with BL, diagnosed at Tygerberg Hospital 
(TBH), South Africa, between 2007 and 2014.33
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Patients and methods
The study was conducted at TBH, the second largest hospital 
in the country and a referral tertiary care institution for 
approximately half of the population of Western Cape 
province.33 We conducted a retrospective analysis of patients, 
diagnosed with BL at TBH from 01 January 2007 to 31 December 
2014 with 2-year follow-up. All children and adults who were 
only diagnosed with BL or Burkitt leukaemia at TBH were 
included. Patients were excluded if the diagnosis of BL could 
not be confirmed and if patients were referred from other 
hospitals after having already been diagnosed with BL.
Case ascertainment and clinical information were derived 
from the Tygerberg Lymphoma Study Group (TLSG) 
database, Stellenbosch University. Paediatric data were 
obtained from the South African Children Cancer Study 
Group (SACCSG) Tumour Registry for all children treated at 
TBH. The National Health Laboratory Services (NHLS) 
electronic database supplemented the TBH clinical records.
Data collection included demographic data (date of birth, age 
at diagnosis and sex), stage as per St Jude modification of Ann 
Arbor staging system or LMB staging, NHLS risk stratification, 
comorbid disease, treatment protocol and outcome.34
The diagnosis was made according to the WHO Classification 
of Tumours of Haematopoietic and Lymphoid Tissues 
2017 criteria for BL (revised 4th edition).11,16
Data collected included initial clinical assessments, 
histology, bone marrow biopsy, cerebrospinal fluid 
cytopathology, computerised tomography of the chest and/
or abdomen and/or pelvis and/or brain if clinically 
indicated. Positron emission tomography/computed 
tomography (PET/CT) scan was rarely used in children but 
commonly used in adults. Leukaemic presentation of BL 
was defined by predominance of bone marrow or peripheral 
blood (> 25% blasts) involvement in the absence of significant 
nodal disease.
The treatment protocol used in children’s group was 
theLMB-96,34,35 whereas different regimens were used in 
adult group, namely LMB-96, hyper-CVAD, Stanford 
V and methotrexate with leucovorin, doxorubicin, 
cyclophosphamide, vincristine, prednisone and bleomycin 
(MACOP-B).10,27,34,35,36,37 The later regimen (i.e. MACOP-B) 
was used in patients who had a poor performance status 
and/or in the elderly.38 All HIV-infected patients received 
ART: all children and adults from 2013 onwards.39
Statistical analysis of all data was performed using Microsoft 
Excel® and the Statistical Software Package SPSS® v 24. 
Results were summarised and presented by year, sex and 
HIV status using descriptive statistical methods. p-values 
were obtained using Pearson’s chi-square and one-sided 
Fisher’s exact calculation methods, in which a value of < 0.05 
indicates statistical significance.
A waiver of individual patient consent was obtained. 
The custodians of the databanks provided consent for the 
retrospective data collection and analysis. All data were 
analysed anonymously using the unique study number 
to ensure protection of the patient privacy.
Ethical considerations
Ethical approval to conduct the study was obtained from the 
Health Research Ethics Committee, Stellenbosch University 
(Reference number: S17/03/046), which complied with 
the principles of the Declaration of Helsinki, 2013.
Results
There were 73 patients initially identified with a diagnosis 
of BL. Five adult patients (7%) were excluded from 
further analysis as only diagnostic specimens were 
available (see Figure 1).
Sixty-eight (100%) patients were analysed, of whom 50 
(73.5%) were adults and 18 (26.5%) were children, with a 
median age of 36 years (range = 2–69 years; interquartile 
range (IQR) = 43−10). Children had a median age of 
5.5 years (range = 2−12 years; IQR = 8−3), whilst adults 
had a median age of 37 years (range = 18–69 years; 
IQR = 42 − 30.5). Overall, 39 patients (74%) were female 
patients and 29 were male patients, with male to female 
ratio of 1:1.3; but this was 3:1 for children and 1.2:1 for 
adults, respectively (p = 0.002).
A lymph node biopsy confirmed the diagnosis of BL in 
59 patients (87%), whilst nine patients (13%) presented 
with Burkitt leukaemia, without nodal involvement, 
including one child. Thirty-four patients (50%) presented 
with pelvic and abdominal involvement, whilst 23 patients 
(34%) presented with facial and neck involvement. 
One patient presented with breast involvement. 
One patient presented with extramedullary thoracic 
(T8–T11) mass.
Forty-seven patients presented with an advanced stage 
disease (III–IV), whilst 21 patients had limited disease 
(I–II). More than half of the children presented with 
limited disease, whilst the majority of patients in the 
adult group were diagnosed with advanced disease (p = 
0.008). Fifty-three patients were HIV-positive, most of 
whom where adults (p = 0.00001) (see Table 1). The mean 
CD4 counts was 250 cells per μL (range = 11–832 cells per 
μL; median = 198 cells per μL). HIV viral load results 
were available in 18 patients, and only five (11%) adults 
were virally suppressed at diagnosis (see Table 2). There 
were six patients with pulmonary TB at diagnosis, of 
whom two were children and four adults.
Seventeen patients (25%), namely two children and 15 adults, 
died prior to the initiation of chemotherapy (see Figure 1). 
Three patients (18%) had limited stage disease, whilst 
14 patients presented with an advanced disease. Causes of 
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death in the two children were bowel perforation with 
septic shock in one patient and complicated TB in other child. 
All 15 of the adults deaths had HIV, and causes of death 
(see Figure 1) were as follows: one died of sepsis; one had 
confirmed Klebsiella pneumonia; one patient had TB with 
confirmed Klebsiella pneumoniae plus methicillin-resistant 
Staphylococcus aureus and TB; one patient had Guillain–Barre 
syndrome with confirmed Acinetobacter baumannii; one 
patient had disseminated TB; one patient had concomitant 
pancreatic head carcinoma; one patient died of bowel 
obstruction with bilateral hydronephrosis and eight patients 
had unknown death causes.
The 2-year overall survival (OS) for the total treated cohort 
was 45% (n = 23). The children had an OS of 69% versus 
adults with an OS of 36%, which was statistically significant 
(p = 0.022) (Table 1). The majority of the survivors (52%) had 
limited disease. Only one of the surviving patients presented 
with Burkitt leukaemia and two-thirds (65%) of the 
survivors had concomitant HIV infection. Treatment 
protocols were the LMB 96 protocol (n = 29) and various 
non-LMB-96 protocols (n = 22) (see Table 2). All children 
(n = 16; 100%) and 13 adults received treatment according to 
the LMB-96 protocol, whilst 22 adults (66%) received non-
LMB-96 protocols. Of the 11 surviving children, treated 
with the LMB-96 regimen, eight presented with limited 
disease, whilst four had concomitant HIV infection. 
Four surviving adults were treated with the LMB-96 
regimen, of whom three presented with advanced disease, 
whilst all had concomitant HIV infection.
The various non-LMB-96 protocols comprised of hyper-
CVAD (n = 11; 50%), Stanford V (n = 8; 36%) and MACOP-B 
(n = 3; 14%) (see Table 3). The eight surviving adults 
presented with advanced disease and seven of eight had 
concomitant HIV infection. Three patients received hyper-
CVAD regimen, three received Stanford V regimen and 
two received MACOP-B regimen. The 2-year OS of the 
patients (n = 8) in the non-LMB-96 protocol was 36%. 
Stanford V and MACOP-B regimens had better survival 
compared to LMB-96 and hyper-CVAD regimens (OS: 45% 
vs. 32%; p = 0.442), but this was not statistically significant 
and sample size was too small.
73
68
Tygerberg hospital 
(TBH) group
51
Treatment group
16
Children
5
Deaths
4-Sepsis; 
1-Tumour 
lysis 
syndrome
Causes of death
11
Alive
35
Adults
12
Alive
23
Deaths
4-Disease progression;
5-Sepsis;
2-Tumour lysis syndrome; 
2- TB;
10-Unknown causes
Causes of death
17
Deaths prior treatment
2
Children
1-Bowel 
obstrucon 
with sepc
shock; 1-TB
Causes of death
15
Adults
1-Bowel obstrucon;
1-Pancreac carcinoma;
4-Sepsis; 
1-Tumour lysis syndrome;
8-Unknown causes 
Causes of death
5†
Excluded, as not 
treated in TBH
18 Children and  55 Adults
†, Five patients were excluded from further analysis as only diagnostic specimens were available as the patients were treated outside Tygerberg Hospital.
FIGURE 1: Schematic outline of Burkitt lymphoma study.
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Twenty-eight patients died during treatment (see Figure 1). 
Two adults and one child died of tumour lysis syndrome 
after receiving debulking chemotherapy. The deaths of 
children, who died during treatment were as follows: 
one child (HIV negative) died of septic shock; one child 
(HIV positive) died of confirmed Klebsiella pneumoniae 
infection; one child (HIV negative) died of neutropenic 
sepsis; one child (HIV positive) died of confirmed 
Acinetobacter baumannii infection with TB and one child 
(HIV negative) died because of renal failure secondary 
to tumor lysis syndrome (TLS) (as mentioned above during 
debulking therapy). The adult deaths during treatment 
were as follows: four died because of disease progression; 
five died of sepsis; two died of tumour lysis syndrome after 
receiving debulking chemotherapy (as mentioned above 
during debulking therapy); two died because of TB and 10 
because of unknown death causes. The causes of death 
amongst the adults in the LMB-96 regimen were as follows: 
two died of tumour lysis syndrome after debulking (as 
mentioned above); one died of sepsis with confirmed 
coagulase-negative Staphylococcus and Acinetobacter 
baumanni infection; one died of pulmonary TB; two died of 
disease progression and three had unknown death causes.
The OS was better in the HIV-negative (57%) patients than 
HIV-positive (41%) patients, although the difference was 
not statistically significant (p = 0.287) (see Table 4). Seven 
surviving children were HIV negative, whilst four had 
concomitant HIV infection. Two children, who died 
had concomitant HIV infection. There was no obvious 
association between OS and HIV status in children (p = 0.676) 
(see Table 5).
Of the 12 surviving adults, 11 had concomitant HIV 
infection, whilst only one was HIV negative (see Table 6). Of 
the 23 adults who died, 20 had concomitant HIV infection, 
whilst three were HIV negative. In some patients 
with known HIV diagnosis, the records of CD4 and HIV 
viral load were not available in the NHLS database, 
suggesting compliance problem, and therefore, it was 
difficult to ascertain the therapy records from local clinic. 
TABLE 3: Outcome by treatment protocol.
Outcome Total  
(n = 51)
Children (n = 16) Adults (n = 35)
Alive (n = 11) Dead (n = 5) Alive (n = 12) Dead (n = 23)
LMB 96 29 11 5 4 9
Hyper-CVAD 11 0 0 3 8
Stanford V 8 0 0 3 5
MACOP-B 3 0 0 2 1
MACOP-B, methotrexate, bleomycin, adriamycin, cyclophosphamide, vincristine, dexamethasone; 
hyper CVAD, hyperfractionated cyclophosphamide, vincristine, cytarabine, doxorubicin.
TABLE 1: Epidemiological characteristics.
Description Total cohort Children Adults p
n = 68 100% Median Range IQR n = 18 26.5% Median Range IQR n = 50 73.5% Median Range IQR
Age (years) - - 36 2–69 40−10.4 - - 5.5 2–12 8−3 - - 37 18–69 43−31 -
Sex - - - - - - - - - - - - - - - 0.001987
Male 29 26 - - - 13 72 - - - 16 32 - - -
Female 39 74 - - - 5 28 - - - 34 68 - - -
Biopsy - - - - - - - - - - - - - - - 0.30363
Lymph node 59 87 - - - 17 94 - - - 42 84 - - -
Bone marrow 9 13 - - - 1 6 - - - 8 16 - - -
Staging - - - - - - - - - - - - - - - 0.00823
Limited 21 31 - - - 10 56 - - - 11 22 - - -
Advanced 47 69 - - - 8 44 - - - 39 78 - - -
HIV status - - - - - - - - - - - - - - - 0.00001
Positive 53 78 - - - 7 39 - - - 46 92 - - -
Negative 15 22 - - - 10 56 - - - 4 8 - - -
CD4 count - - - - - - - - - - - - - - - 0.60290
< 200 cells/uL 22 50 - - - 1 25 - - - 21 53 - - -
> 200 cells/uL 22 50 - - - 3 75 - - - 19 47 - - -
HIV viral load - - - - - - - - - - - - - - - 0.75820
Detectable 13 72 - - - 5 100 - - - 8 61 - - -
Undetectable 5 28 - - - 0 0 - - - 5 39 - - -
Outcome (n = 51) - - - - - - - - - - - - - - - 0.02170
Alive 23 45 - - - 11 69 - - - 12 35 - - -
Deaths 28 55 - - - 5 31 - - - 23 65 - - -
Deaths - - - - - - - - - - - - - - - 0.58400
Prior treatment 17 38 - - - 2 29 - - - 15 39 - - -
during/after 
treatment 
28 62 - - - 5 71 - - - 23 61 - - -
TABLE 2: Human immunodeficiency virus status of human immunodeficiency 
virus-infected patients.
Description Total cohort (n = 53) Children (n = 7) Adult (n = 46)
n % n % n %
CD4 count
> 200 cells/uL 21 40 2 29 19 41
< 200 cells/uL 23 43 2 29 21 46
Unknown 9 17 3 42 6 13
Viral load
Undetectable 5 9 0 0 5 11
Detectable 13 25 5 71 8 17
Unknown 35 66 2 29 33 72
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Human immunodeficiency virus therapy information was 
not available at the time of diagnosis, and the treatment was 
initiated as soon as the diagnosis of HIV was confirmed.
The six patients with TB infection had concomitant 
HIV infection, whilst only one presented with limited disease. 
Of the four adults who had TB, two died prior to initiation 
of treatment, whilst two died during treatment. Of the two 
children who had TB, one died prior to initiation of treatment 
whilst one died during treatment.
Discussion
Burkitt’s lymphoma is the third most common paediatric 
lymphoma in South Africa according to South African 
Children’s Tumour Registry and the commonest HIV-related 
lymphoma (HRL) seen in adult population followed 
by diffuse large B-cell lymphoma subtypes as reported by 
TLSG (2002–2009).40,41 In the Western Cape province, 
sporadic  BL (61%) was more common in children and 
immunodeficiency-associated BL (93%) predominated in 
the adult population, which is demonstrated in this single-
centre study.41 In non-endemic areas, BL accounts 40% – 50% 
of childhood NHLs.6 In the United States, BL comprises 30% 
of paediatric lymphomas and < 1% of adult NHLs.42
The peak incidence was in the three to eight age groups for 
children and in the 31–43 age groups for adults. The male to 
female ratio was higher in the children as compared to adults 
(3:1 vs. 1:2.2; p = 0.002). The study conducted in Southern and 
Eastern Europe showed peak age of 5–9 years,43 whilst the 
American study reported 4–7 years peak age in sporadic BL 
variant with male to female ratio of 2:1.844 and similar 
patterns are seen in African studies.45 The predominance of 
women infected by HIV reflects the South Africa national 
demographics of HIV prevalence46 and is comparable to 
other South African47,48 and international studies.49
A predominance of presentation in abdominal and pelvic 
sites rather than in the jaw distinguishes this study of 
South African patients from those reported from endemic 
regions in Africa.8,24 Breast tissue involvement was rarely 
seen in our study.24 Leukemic presentation of BL in the 
absence of a tissue involvement (pure Burkitt leukaemia) is 
very rare. This study identified nine patients with pure 
Burkitt leukaemia. One HIV-positive adult, with Burkitt 
leukaemia achieved complete remission.2
The sporadic form and limited disease (stages I and II) 
predominated (56%) in children, whilst immunodeficiency-
associated variant and advanced disease predominated 
(78%) in adults (p = 0.008) with the latter showing poorer 
outcome. Similar patterns were observed in the United 
States, in which a multi-variable analysis found that 
younger age was associated with lower mortality, whilst 
older age, black race and advanced stage were associated 
with higher mortality.50 A Brazilian study reported complete 
remission in 38 children (84.4%) with 35 months follow-
up.51 In contrast to our findings, a French study observed 
a 2-year survival rate of 70% in a large prospective series of 
72 adult BL patients treated with the French adapted 
paediatric LMB protocol base.26
The average age (37 years) and median CD4 count (198 cells 
per uL) are similar to other studies of adult HIV-associated 
BL.49,52 Poor prognostic factors in adult HIV patients are 
similar to our study, namely CD4 count < 200, opportunistic 
infection (e.g. TB), bone marrow involvement, extranodal 
spread and poor general health.
The 2-year OS rate for our 37 patients with HIV-associated BL 
was 41%, which is lower than that reported by American 
study in whom 34 patients survived (69%).53 This is difficult 
to compare with international studies because of lack of 
data on CD4 counts, antiretroviral (ARV) therapies and HIV 
viral load in our study. Our study included six children with 
HIV-associated BL, who received intensive chemotherapy. 
No statistically significant difference was observed amongst 
children in relation to HIV status and outcome (p = 0.899). 
There are few case reports of children with immunodeficiency-
associated BL in the world.54,55,56
The sample size of HIV-negative adults (n = 4) could not 
be reliably analysed and additional research is required. 
An international study of 52 immunocompetent adults 
with BL showed an event-free survival rate of 65% at 
2 years.27,52 One European study included 13 patients with 
immunodeficiency-associated Burkitt’s lymphoma, who are 
reported to have a worse outcome than those with other 
variants of the disease.57 Human immunodeficiency 
virus–positive patients (on ART and virally suppressed) are 
seen to have similar outcomes to their HIV-negative 
counterparts as well as the fact that the use of ART with 
chemotherapy may be associated with a favourable outcome. 
The study also noted that the administration of ART was not 
associated with any significant increase in toxicity.57 The 
authors concluded that hyper-CVAD was highly effective 
within this context.
TABLE 4: Outcome by human immunodeficiency virus (HIV) status in treatment 
group.
Outcome Total (n = 51) Dead (n = 28) Alive (n = 23) p
n % n % n %
Positive 37 73 22 79 15 65 0.287
Negative 14 27 6 21 8 35
TABLE 6: Outcome by human immunodeficiency virus (HIV) status in adults.
Outcome Total (n = 35) Dead (n = 23) Alive (n = 12) p
n % n % n %
Positive 31 89 20 87 11 92 0.677
Negative 4 11 3 13 1 8
TABLE 5: Outcome by human immunodeficiency virus (HIV) status in children.
Outcome Total (n = 16) Dead (n = 5) Alive (n = 11) p
n % n % n %
Positive 6 37 2 40 4 64 0.899
Negative 10 63 3 60 7 36
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One quarter of patients (25%) demised before the initiation 
of chemotherapy (early deaths) because of disease-related 
complications and/or associated co-morbidities. Factors 
that may have delayed the initiation of chemotherapy in 
adults include late presentation with advanced disease, 
poor general condition, spontaneous tumour lysis, renal 
impairment and complications of HIV infection. Sepsis was 
the cause of death in 80% of children, whilst both sepsis and 
disease progression were the cause of death in 39% of 
adults, suggesting that good outcomes may still be achieved 
in the resource-limited settings. This remains a serious 
concern in HIV-positive patients and other frail patients 
who are more prone to infectious complications.42
This retrospective study of children and adults with BL 
showed a 2-year OS of 45.1% with a better survival for 
children (69%) than adults (34%) (p = 0.022). Our study 
showed that paediatric group had an outcome comparable to 
GFAOP study (overall survival: 69% vs 61%), importantly 
both studies used similar treatment protocol (LMB 
protocol).35,45 More than one-third (n = 13) of our adult group 
were treated with adapted paediatric LMB protocol, four 
patients achieved a 2-year survival; this was lower than the 
study of an adapted paediatric LMB protocol which showed 
an event-free survival rate of 65% at 2 years amongst 72 
adults with BL.19 Hyper-CVAD group (n = 11) showed 36% 
overall outcome; these findings are in contrast with a similar 
study conducted by Thomas et al. in which hyper-CVAD 
alone showed 53% OS, whilst hyper-CVAD plus rituximab 
was reported at 86% OS.58
It is important to note that none of our treatment regimens 
included rituximab, which was not available because of cost 
constraints. Some studies suggested that addition of 
rituximab to standard regimens for BL improves survival.4,5,59 
The cost associated with rituximab makes this approach 
challenging in LMICs.
Treatment of AIDS-related malignant lymphoma remains a 
therapeutic challenge, and no data exist on patients with 
HRL suffering from active opportunistic infections.57 South 
Africa has the highest number of reported multi-drug-
resistant TB cases globally.39 The burden of disease in South 
Africa because of HIV and TB is high, and these diseases 
present with similar clinical features as BL. In our study, 
patients with comorbid TB had the poorest outcome. 
Therefore, a larger cohort is required to determine the 
significance of these findings.
Major limitations to our study remain a small sample size 
and the retrospective nature of the study as well as 
unavailable data.
Conclusion
In summary, our study demonstrates better cure rates for BL 
in children than adults, irrespective of HIV status, with 
statistical significance (p = 0.022). Of note, all children were 
treated with a single protocol. This is difficult to do in adults 
because of the varying presentations and co-morbidities in 
the adult group, and thus, therapy needs to be stratified to 
avoid undue toxicity.
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